Literature DB >> 626239

Possible withdrawal from endogeneous opiates in schizophrenics.

M Gitlin, M Rosenblatt.   

Abstract

Mesh:

Substances:

Year:  1978        PMID: 626239     DOI: 10.1176/ajp.135.3.377

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  5 in total

1.  Naloxone enhancement of DMT and LSD-25 induced suppression of food-rewarded bar pressing behavior in the rat.

Authors:  D Ruffing; B Kovacic; S Demetriou; E F Domino
Journal:  Psychopharmacology (Berl)       Date:  1979-04-25       Impact factor: 4.530

2.  Assessment of naltrexone in the treatment of schizophrenia.

Authors:  M J Gitlin; R H Gerner; M Rosenblatt
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 3.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

Review 4.  New and experimental therapeutic roles for naloxone and related opioid antagonists.

Authors:  L F McNicholas; W R Martin
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

5.  Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.

Authors:  Samuel D Clark; Jared X Van Snellenberg; Jacqueline M Lawson; Anissa Abi-Dargham
Journal:  Neuropsychopharmacology       Date:  2020-06-09       Impact factor: 7.853

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.